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Abstract
Despite antiretroviral medications, the rate of pediatric HIV-1 infections through breast-milk
transmission has been staggering in developing countries. Therefore, the development of a vaccine
to protect vulnerable infant populations should be actively pursued. We previously demonstrated
that oral immunization of newborn macaques with vesicular stomatitis virus expressing simian
immunodeficiency virus genes (VSV-SIV) followed 2 weeks later by an intramuscular boost with
modified vaccinia ankara virus expressing SIV (MVA-SIV) successfully induced SIV-specific T
and B cell responses in multiple lymphoid tissues, including the tonsil and intestine [13]. In the
current study, we tested the oral VSV-SIV prime/systemic MVA-SIV boost vaccine for efficacy
against multiple oral SIVmac251 challenges starting two weeks after the booster vaccination. The
vaccine did not prevent SIV infection. However, in vaccinated infants, the level of SIV-specific
plasma IgA (but not IgG) at the time of challenge was inversely correlated with peak viremia. In
addition, the levels of SIV-specific IgA in saliva and plasma were inversely correlated with viral
load at euthanasia. Animals with tonsils that contained higher frequencies of SIV-specific TNF-α-
or IFN-γ-producing CD8+ T cells and central memory T cells at euthanasia also had lower
viremia. Interestingly, a marked depletion of CD25+ FoxP3+ CD4+ T cells was observed in the
tonsils as well as the intestine of these animals, implying that T regulatory cells may be a major
target of SIV infection in infant macaques. Overall, the data suggest that, in infant macaques orally
infected with SIV, the co-induction of local antiviral cytotoxic T cells and T regulatory cells that
promote the development of IgA responses may result in better control of viral replication. Thus,
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future vaccination efforts should be directed towards induction of IgA and mucosal T cell
responses to prevent or reduce virus replication in infants.
Introduction
Antiretroviral therapy (ART) provided to the HIV-1-infected mother and/or her newborn
child can dramatically reduce the risk of HIV vertical transmission [1-3]. A large clinical
trial in Malawi recently demonstrated that vertical transmission of HIV could be further
reduced if the period of ART to the newborn was extended for several weeks [4,5].
However, in many resource-poor countries, access to ART is still limited. Thus, pediatric
HIV infections continue to occur at a staggering rate. Considering that there is no HIV
vaccine available for preventing HIV transmission in adults, and that the majority of newly
infected people are women of child-bearing age, the development of a pediatric HIV vaccine
should be pursued in parallel with improved antiretroviral intervention strategies and adult
HIV vaccine development [6-10].
A large proportion of pediatric HIV infections are due to breast milk transmission. In infant
rhesus macaques, the tonsil and intestinal tissues represent the primary sites of viral
replication after oral SIV infection [11]. Therefore, we reasoned that a vaccine intended to
prevent oral HIV infection of infants should induce immune responses at these sites. A
pediatric HIV vaccine should also be administered as early after birth as possible, with
accelerated boosting intervals, to protect the newborn against the frequent and continuous
exposure to HIV in breast milk.
We previously showed that systemic administration of poxvirus-based SIV vaccine
candidates to newborn macaques provided partial protection against oral SIV challenge and
prolonged the survival of infants that became infected [12]. Recently, we demonstrated that
an oral prime with replication-attenuated Vesicular Stomatitis Virus vector containing
multiple SIV genes (VSV-SIV), followed by a systemic boost with Modified Vaccinia
Ankara virus containing SIV genes (MVA-SIV) induced SIV-specific T and B cell
responses in blood and tissues of infant macaques [13]. Although SIV-specific T cell
responses were relatively low, they were detectable in multiple lymphoid and mucosal
tissues. Systemic antibody responses to SIV were consistently induced in all vaccinated
animals by 4 weeks. Therefore, in the current study, we used a new cohort of infant
macaques to test whether the neonatal VSV-SIV/MVA-SIV vaccine regimen was effective
for preventing oral SIV infection. While vaccine-induced immune responses did not prevent
infection and viral dissemination, the vaccinated animals with SIV-specific IgA at the time
of oral challenge, and with mucosal and systemic SIV-specific antibody and T cell responses
after challenge had lower levels of virus replication than animals in which T and B cell
responses were low and detected in fewer tissues.
Materials and Methods
Animals
Newborn rhesus macaques (Macacca mulatta), born to animals from the HIV-2, SIV, type D
retrovirus, and simian T-cell lymphotropic virus type 1 free colony, were hand-reared in the
nursery of the California National Primate Research Center (CNPRC) as previously
described [14]. The animals were housed in accordance with the standards set forth by the
American Association for Accreditation of Laboratory Animal Care, and all procedures
were approved by the Animal Use and Care Committee at UC Davis. For blood collections
and immunizations, animals were immobilized with 10 mg/kg of ketamine-HCL (Parke-
Davis, Morris Plains, NC) given by the intramuscular (i.m.) route. A total of 16 infant
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macaques were included in the vaccination study. Group 1 animals were immunized with
VSV-SIV/MVA-SIV. Age-matched placebo control animals (Group 2) received mock
immunizations (see below). Both male and female infant macaques were assigned to groups
randomly. The MHC haplotype at the time of birth was unknown and thus, could not be
considered in the group assignment. Subsequent MHC typing revealed that 2 animals in the
vaccine group and 3 animals in the control group were positive for the MamuA*01 allele
(Table 1). Animals were not typed for MamuB*08 or B*17.
Immunizations
Animals in Group 1 were immunized within 6 days of birth with VSV-SIV. The vaccine was
administered orally in a volume of 1 ml containing107 plaque-forming units (PFU) of each
recombinant VSV construct: VSV-SIVmac239gag, -SIV mac239pol, -SIVmac239envG-1
(SIV env inserted in lieu of the VSV G gene). Two weeks later, animals were given an i.m.
booster vaccination with 1 ml recombinant MVA-SIV vaccine consisting of 108 infectious
units (IU) of MVA-SIVmac239gag-pol (termed vJH4) plus 108 IU of MVA-SIVmac239env
[12,15]. The MVA-SIV was injected in 250 μl volumes at 4 sites. The naive control animals
in Group 2 were orally or i.m. immunized with 1 ml RPMI1640 at the same time points.
Empty vectors were not used for mock immunizations as in our previous study [13] because
it was not possible to justify the inclusion of more valuable nonhuman primates as infection
controls before confirming that the potential vaccine had any efficacy.
SIVmac251 oral challenge
Two weeks after the 2nd immunization, all animals were repeatedly challenged by the oral
route with SIVmac251 as previously described [11,12]. Briefly, animals were bottle-fed 3
times per day, for 5 consecutive days, in a 2 ml volume of 104 TCID50 SIVmac251 in a 1:1
mixture with RPMI1640 in sucrose. The uncloned SIVmac251 (stock 6/04) was propagated
in rhesus PBMC and had been titrated in vitro and in vivo to confirm infectivity. This virus
stock was similar to the SIVmac251 stocks that were used for oral SIV challenge in our
prior studies as it was derived from the same seed stock (Table 2).
Sample collection and processing
EDTA anticoagulated blood samples were collected weekly or biweekly based on allowable
blood volumes. Plasma was harvested after centrifugation of the blood and stored
immediately at -80°C for antibody and virological assessment. The cellular blood fraction
was resuspended in Dulbecco’s phosphate-buffered saline (DPBS) lacking Ca2+ and Mg2+.
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient
centrifugation using Lymphocyte Separation Medium (MP Biomedicals, Solon, OH). PBMC
were washed twice with DPBS followed by complete RPMI (RPMI 1640 supplemented with
10% FBS, penicillin, streptomycin and L-glutamine).
To measure immune responses in various tissues, animals were euthanized approximately
8-10 weeks after they became infected. At the time of euthanasia, the following tissues were
collected: tonsils, submandibular lymph nodes (LN), retropharyngeal LN, axillary and
mesenteric LN, and intestinal tissues (ileum, colon). Tissue cell suspensions were prepared
as previously described [13]. Briefly, LN were carefully dissected with scalpels, passed
through a cell strainer (40 μm), and washed twice with complete RPMI 1640. Intestinal
tissues were thoroughly rinsed with DPBS, cut into small pieces with scalpels, and subjected
to a total of 3 digestions for 30 minutes at 37°C in 30 ml of RPMI 1640 supplemented with
7.5% FBS, antibiotics, amphotericin B, and 0.5 mg/ml collagenase type II (Sigma, St. Louis,
MO). After each digestion, the supernatant containing released cells was transferred into a
fresh centrifuge tube and washed twice with PBS. After three digestion steps, the cells were
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combined and centrifuged on a gradient of 65% and 35% Percoll (Sigma). Lymphocytes
were collected from the interphase and washed twice.
Saliva was collected at euthanasia for mucosal antibody assessment. Saliva was collected
using sterile, cellulose acetate absorbent Weck-Cel sponges [16]. Two sponges were used to
sample salivary fluid from each infant by placing them between the cheek and gum on the
side of the mouth where saliva is pooling. The sponges were allowed to absorb fluid for a
minimum of 5 minutes. After this time, the sponges were placed inside a 5 ml tissue culture
tube, placed on ice, then stored at -80°C. Secretions were extracted as previously described
[16]. Briefly, sponges were thawed and eluted by ultracentrifugation with buffer in the upper
chamber of a Corning SpinX 0.45μm microspin filter assembly. The secretion was aliquoted
and stored at -80° C for analysis of SIV-specific antibodies and total immunoglobulin (Ig)
by ELISA. Note that saliva was not collected at the time of challenge to avoid causing
micro-abrasions that could facilitate viral entry in the oral cavity. In addition, we have found
that infant macaques rarely have sufficient total IgA in saliva at this time (4 wks after birth)
to detect specific antibody (Kozlowski, unpublished data). Sampling other mucosal sites
(e.g. rectal mucosa, lung) would not have provided data relevant to oral SIV infection and
thus did not justify the exposure of infant macaques to invasive procedures that could
jeopardize the animals’ health and the study outcome.
SIV-specific antibodies and total IgA
The concentrations of anti-SIV envelope (Env) or anti-SIV Gag,Pol antibodies in plasma or
saliva were quantitated by ELISA as described [17] using micotiter plates coated
respectively with 100ng/well of SIVmac251 rgp130 (ImmunoDiagnostics, Woburn, MA) or
100μl/well of 1/400 SIVmac239 whole viral lysate (Advanced Biotechnologies Inc.,
Columbia, MD), which does not contain detectable Env protein at this dilution. For total IgA
ELISA [16], plates were coated with goat anti-monkey IgA (AlphaDiagnostic, San Antonio,
TX). Previously calibrated preparations of macaque sera containing known amounts of
antibody or IgA were used to generate standard curves in these assays [17]. The plates were
developed with biotinylated affinity-purified goat anti-monkey IgA antibody
(AlphaDiagnostic) or -human IgG (SouthernBiotech, Birmingham, AL), avidin-peroxidase
(Sigma), and TMB (KPL, Gaithersburg, MD). The plates were read in a SpectraMax M5
plate reader (Molecular Devices, Sunnyvale, CA) and concentrations of antibody in
specimens were interpolated from 4-parameter standard curves constructed with the
SoftMax Pro computer program (Molecular Devices). The specific activity for IgA in saliva
or plasma was calculated by dividing the concentration of SIV-specific IgA antibody in the
sample by the total IgA concentration. A sample was considered to have significant specific
activity if it was ≥ mean + 3SD for negative controls and 3.4-fold greater than the animal’s
preimmune value. The specific serum IgG antibody concentration was considered significant
if it was 3.4-fold greater than the preimmune concentration.
Flow cytometric assessment of immune activation and SIV-specific T cell immune
responses
Phenotypic characterization of T cell populations was combined with the analysis of SIV-
specific immune responses. To assess T cell activation, 1×106 cells were stained with CD3
(clone SP34.2)-PacificBlue, CD4 (clone L200)-PE-Cy7, CD8 (clone TPA8)-Alexa 700,
Ki67 (clone B56)-FITC, and CCR5 (clone 3A9)-PE. T cell differentiation was evaluated by
using CD45RA (clone L48) and CCR7 (clone 3D12) antibodies to distinguish naïve
(CD45RA+ CCR7+), central memory (CD45RA- CCR7+) and effector/effector memory
(CD45RA+/- CCR7-) T cells. Regulatory T cells (Treg) were characterized as CD3+ CD4+
CD25+ FoxP3+ cells. The CD25 and FoxP3 antibodies were from Miltenyi (clone A251;
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Miltenyi Biotech Inc., Auburn, CA) and BioLegend (clone 206D; BioLegend, San Diego,
CA), respectively, all other antibodies were from Beckton-Dickinson (San Jose, CA).
To measure SIV-specific T cell responses by intracellular cytokine staining, PBMC and
tissue cell suspensions (1×106 cells) were stimulated in vitro in the presence of 0.5 μg/ml of
anti-CD49d and anti-CD28 antibodies with either 300 ng/ml aldrithiol 2-inactivated
SIVmac239 (kindly provided by Dr. Jeff Lifson, NCI) or with 5 μg/ml of pooled,
overlapping SIV Gag p27 peptides (NIH AIDS Research and Reference Reagent Program).
Control cultures were stimulated with medium only (negative control) or with 50 ng/ml
PMA plus 250ng/ml ionomycin (positive controls; Sigma). Cells were cultured for 6 hours
at 37°C and 5% CO2 with 10 μg/ml Brefeldin A (Sigma) being added 1 hour after culture
initiation. Note that Beckton-Dickinson protocols were followed for all staining panels
except the regulatory T cell panel, which was done according to Biolegend protocols. CD4+
and CD8+ T cells were evaluated for the production of IFN-γ and TNF-α in response to SIV
antigen stimulation. Samples were acquired on a FACS ARIA instrument (Beckton-
Dickinson). A total of 30,000 events were acquired for T cell activation and regulatory T
cells, and 300,000 events were acquired to assess SIV-specific T cell responses. Data were
analyzed using FlowJo software (TreeStar, Ashland, OR). Boolean gating was used for
determining frequencies of multifunctional cells. Frequencies of cytokine-positive cells are
reported as the percentage within CD4+ or CD8+ T cell populations. Antigen-stimulated
cells were considered positive if the percentage of cytokine-positive cells was 2-fold greater
than the percentage in the unstimulated medium control and if the percentage was ≥ 0.04%
after subtraction of the medium control value.
Virological analysis
Plasma samples were analyzed for SIV RNA by a real time reverse transcriptase polymerase
chain reaction (RT-PCR) assay as described [18]. Data are reported as viral RNA copies per
ml of plasma.
Statistical analysis
Individual parameters in a single tissue at specific time points were compared between
control and vaccinated macaques using the Mann-Whitney test. One-way ANOVA with
subsequent Tukey comparisons was applied to define statistical differences for an individual
parameter across multiple tissues. To compare virus replication levels over time between
vaccinated and unvaccinated macaques, area-under-the-curve (AUC) was calculated for
log10 SIV plasma RNA levels from day 0 through week 8 after infection. Area-under-the-
curve values were also calculated for logarithmically transformed plasma IgG and IgA
antibody concentrations from week 0 - 8 after SIV challenge and compared between groups
using the Mann-Whitney test. Weight gain of animals in the two groups was compared using
linear regression analysis. All statistical analyses, including the testing for correlations
between two parameters, were performed using GraphPad Prism and InSTAT Software
(GraphPad, Inc., La Jolla, CA). P values less than or equal to 0.05 were considered
significant.
Results
Limited effect of VSV-SIV/MVA-SIV vaccination on viremia in infant macaques orally
challenged with SIV
Repeated oral exposure of naive infant macaques to SIVmac251 resulted in systemic
infection in 6/8 animals within two weeks of the first SIV exposure (Figure 1A). The 2
virus-negative animals (#37919 and #38125) were exposed to a second round of 15 oral SIV
exposures at 7 weeks of age (3 weeks after the first challenge round). Both animals became
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infected within two weeks (Figure 1A; gray lines). Peak viremia and viral set point ranged
from 106 - 108 copies of viral RNA per ml of plasma in all animals, including the
rechallenged animals, which had peak viremia of 6.7 and 7.8 log10 viral RNA copies/ml
after the second round of challenge (Figure 1A and Table 1). Vaccination of infant
macaques with VSV-SIV/MVA-SIV did not prevent infection after oral SIV exposure. As in
the control macaques, 6/8 vaccinated animals became systemically infected after 15 oral SIV
exposures, and the remaining 2 vaccinees (#38129 and #38130) were infected after a second
round of challenges (Figure 1B). Based on our experience with this oral SIV challenge
model in infant macaques, we are confident that the 2 naive and 2 vaccinated animals which
received two rounds of oral SIV exposures were infected after the second round, as opposed
to exhibiting delayed infection after the first round. Thus, in all Figures and data discussions,
the post-challenge results for these animals (designated by gray color) correspond to weeks
after the second round of challenge. This facilitated comparison of results for all animals in
the study.
One of the 8 vaccinated macaques (#38129) reached a viral set point below 106 viral RNA
copies per ml, and 3 other vaccinated animals reached a set point near 106 copies per ml, the
lower limit of viremia in the naive macaques (Figure 1). There were were no statistically
significant differences in peak viremia or viral set point between the vaccinated and
unvaccinated macaques. There was a trend, however, towards lower average plasma viral
loads in vaccinated compared to unvaccinated animals between weeks 4 to 8, and this
difference reached statistical significance at the week 8 post-challenge time point
(P=0.0321) (Figure 1C). Area-under-the curve- analysis (AUC) of plasma viremia until
week 8 similarly showed a trend towards slightly better control of virus replication in
vaccinated compared to unvaccinated macaques (Table 1). As animal numbers declined after
week 8, later time points were excluded from the analysis. The MHC genotype did not
appear to play a role in vaccine-mediated control of virus replication. The 2 naive control
animals with the lowest levels of virus were MamuA*01-positive. However, in the vaccine
group, the animal (#37898) with the highest viral load was also MamuA*01-positive.
Consistent with the plasma viral RNA levels, vaccinated animals showed a higher average
weight gain compared to the naive animals (Figure 1D, P<0.01 by linear regression
analysis). Weight gain is considered a critical clinical parameter in pediatric studies as
failure to thrive is generally associated with a poorer prognosis.
SIV-specific T cell responses
a) Vaccine-induced T cell responses in blood prior to challenge—We recently
showed that oral VSV-SIV prime/systemic MVA-SIV boost in infant macaques induces
SIV-specific CD4+ and CD8+ T cells in lymph nodes draining the oral cavity in addition to
systemic lymphoid tissues and blood [13]. In the current study, the presence of SIV-specific
T cells in tissues could not be assessed before challenge because it is not feasible to obtain
biopsies from infant macaques at this early age without compromising survival. SIV-specific
T cell responses were detected in blood of 3 of 8 vaccinated infants at the time of oral SIV
challenge (Table 1). However, the frequencies of SIV-specific T cells in blood at the time of
challenge did not correlate with viral replication after infection.
b) T cell responses in blood after oral SIV challenge—After challenge, 6 of 8
vaccinated macaques demonstrated SIV-specific T cell responses (Figure 2A). These
postchallenge SIV-specific T cell responses in blood could not be predicted based on
prechallenge SIV-specific T cell responses in blood (Table 1). Over time, SIV-specific T
cells in blood waned and were evident in only 2 of 8 vaccinated animals at euthanasia (Table
1).
Marthas et al. Page 6













SIV-specific T cell responses in blood of naive infant macaques were similar to those in the
vaccinees. SIV-specific T cell responses were observed in 6 of 8 controls after challenge,
but at the time of euthanasia they were detected in only 1 control animal (Table 1, Figure
2B). The similar antigen-specific CD8+ T cell responses in vaccinated and naive macaques
(Figures 2A and B) is consistent with the finding that CD8+ T cells in both groups were
comparably activated after SIV challenge (Figures 2C and D). In all vaccinated and control
animals, the frequencies of CCR5+ and Ki67+ CD8+ T cells in blood rapidly increased 1-2
weeks after oral SIV infection and then returned to baseline levels (Figures 2C and 2D).
c) SIV-specific T cell responses in lymphoid tissues at the time of euthanasia
—Overall, 7 of 8 vaccinated infants had SIV-specific CD4+ and/or CD8+ T cell responses in
at least one tissue examined at euthanasia. Due to insufficient cell numbers, the presence of
specific T cells in tonsils could only be analyzed in 5 of the vaccinated animals (#38129,
#37907, #38141, #37902, #37908). In regard to the tissues most proximal to probable sites
of viral entry, 5 of 8 vaccinated macaques had SIV-specific T cell responses in lymph nodes
draining the oral cavity (tonsil, submandibular LN) and 4 of these macaques also had SIV-
specific T cells in the ileum (Table 1). In contrast, only 3 of 8 naive animals demonstrated
SIV-specific CD8+ T cells in tissues, and these were observed in fewer tissues (Table 1).
However, 2 additional control animals mounted CD4+ T cell responses to SIV. Thus, SIV-
specific T cell responses were detected in submandibular lymph nodes of 4 of 8 and in the
ileum of 2 of 8 naive controls. None of the 4 tonsil specimens from unvaccinated macaques
(#38115, #37919, #38128, #37921) had SIV-specific T cells (Table 1), including the 2
animals with the lowest virus loads in blood (MamuA*01-positives #37919 and #38115).
Overall, in both vaccinated and unvaccinated animals, SIV-specific T cells were induced in
relatively low frequencies (Table 1), and the majority of SIV-specific T cells produced only
a single cytokine, with TNF-α responses dominating over IFN-γ responses (data not shown).
The 3 vaccinated macaques (#38129, 37907, and 38141) with SIV Gag p27-specific T cell
responses in the tonsil had the lowest viral loads at the time of euthanasia (Figure 1, Table
1). Also, there were higher frequencies of central memory (TCM), and lower frequencies of
effector/effector memory (TEff) CD4+ and CD8+ T cells in the tonsil of vaccinated (but not
unvaccinated) macaques, and both of these were associated with lower levels of virus
replication (Figure 3). TCM are functionally characterized by more persistent IL-2
production compared to effector T cells [19]. In the current study though, IL-2 production
by antigen-specific cells was not measured. Based on phenotypic markers, SIV-specific
TNF-α and IFN-γ producing cells were found in both TCM (CD45RA- CCR7+) and TEff
CD8+T cell populations (CD45RA+/- CCR7-) (Figure 4). Together, these T cell data for
vaccinated macaques are consistent with the potential for local immune responses at the site
of virus exposure to control virus replication.
The overall slightly broader tissue detection of SIV-specific T cells in the vaccinated
compared to unvaccinated macaques (Table 1) suggests that these responses reflected
vaccine-induced memory T cell responses. Although these tissue responses were only
measured at the time of euthanasia, this conclusion is consistent with the detection of
VSVSIV/ MVA-SIV-induced SIV-specific T cell responses in multiple tissues at 4 weeks of
age in our prior study [13], which was the time of challenge here.
Thus, although vaccine-induced T cells did not prevent infection, there were some
noteworthy differences in post-challenge SIV-specific tissue T cell responses between
vaccinated and unvaccinated infant macaques that could have contributed to reduced viremia
in some vaccinated animals.
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a) Vaccine-induced antibodies at the time of oral SIV challenge—We have
already demonstrated that VSV-SIV/MVA-SIV vaccination of infant macaques induces
SIV-specific IgG and IgA responses to SIV Env and Gag,Pol proteins [13]. Consistent with
these data, all vaccinated infant macaques in this study had detectable SIV-specific IgG
antibodies in plasma at the time of challenge (Figure 5A). In addition, most (6/8) vaccinated
animals had detectable, albeit low, levels of SIV Env-specific IgA in plasma (Figure 5B).
Importantly, in these 6 animals, SIV-specific plasma IgA antibody levels at the time of
challenge, despite being low, were inversely correlated with acute peak plasma viral RNA
levels (Figure 6A). This inverse correlation between SIV Env-specific plasma IgA at the
time of challenge and viremia was still evident when animals reached viral set-point at week
4 after oral SIV challenge (P=0.02, r=-0.8822). In contrast, SIV-specific plasma IgG
antibody levels at the time of challenge did not correlate with peak viremia (Figure 6B).
b) SIV-specific systemic and mucosal antibody responses after SIV challenge
—Within the first 2-4 weeks after challenge, SIV-specific IgG further increased in plasma of
all vaccinated animals (Figure 5). SIV Env and Gag,Pol-specific plasma IgG AUC levels
from weeks 0 - 8 were significantly higher in vaccinated than unvaccinated macaques
(P=0.0002 and P=0.003, respectively; Table 1). Moreover, 3 of 8 naive macaques (#38112,
38122, and 38125) failed to develop SIV-specific IgG throughout the study and these had
the highest plasma viremia (Table 1). The SIV-specific plasma IgA was detected in all
vaccinees and reached higher levels compared to control macaques (Figure 5B, P=0.01 for
AUC analysis of SIV Env-specific IgA; Table 1). Further, in contrast to vaccinated
macaques, only 50% of the unvaccinated macaques developed SIV-specific IgA antibodies
in plasma after oral SIV challenge.
At the time of euthanasia, SIV-specific IgA antibodies were detected in saliva from 5 of 8
vaccinated but only 3 of 8 unvaccinated macaques (Table 1, Figure 6). Some IgA
transudation from serum into saliva likely occurred in these animals; however, local IgA
production was suggested by the higher specific activity of SIV-specific IgA in saliva
compared to plasma (Figures 6C and 6D). Consistent with the inverse correlation between
SIV Env-specific IgA at the time of challenge and peak viremia, higher SIV Env and Gag,
Pol-specific plasma IgA in vaccinated macaques at the time of euthanasia correlated with
better control of virus replication (Figures 6E and 6F). In the 3 vaccinated animals with the
highest viral loads, SIV Env-specific IgA increased only slightly (#37908, #37898) or not at
all (#38142) (Figure 5B).
The 3 vaccinated animals with the highest SIV-specific plasma IgG and IgA antibody levels
throughout the post-challenge period and with high salivary IgA levels at the time of
euthanasia (#38129, 37907, and 38141) also had SIV Gag p27-specific CD8+ T cell
responses in the tonsil (Table 1). The finding of both SIV-specific tonsillar CD8+ T cell and
salivary IgA responses in animals with lower viremia suggests an association between
mucosal immunity and reduced virus replication. Alternatively, animals with higher viremia
could have suffered more rapid loss of CD4+ T helper cells, which could have reduced SIV-
specific immune responses.
CD4+ T cell loss in blood and tissues
In infant macaques, the loss of CD4+ T cells due to SIV infection must be examined in
relation to normal developmental changes in cell populations during the first few months of
life. At birth, rhesus macaques, like humans [20-23], have very high frequencies of CD4+ T
cells in blood and tissues when compared to CD8 T+ cells. Within the first few months of
life, the high CD4:CD8 T cell ratio decreases to approximate that in adults [11]. In the
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current study, the percentage of CD4+ T cells in blood of infants decreased from birth to one
month of age, the time when they were challenged (Figure 7A). After SIV challenge and
infection, both the percentages and absolute numbers of total CD4+ T cells in blood were
relatively stable (Figure 7A and 7B). We did, however, observe a decrease in the frequencies
of CCR5+ and Ki67+ CD4+ T cells in blood within the first 2 weeks of oral SIV infection
(Figures 7C and 7D). This loss of activated blood CD4+ T cells was similar in vaccinated
and naive control macaques after infection. At euthanasia, the loss of CD4+ T cells in
various tissues was also comparable in vaccinated and unvaccinated macaques (Figure 8A).
As expected, CD4+ T cell depletion was greatest (>70%) in intestinal tissues [24]. In
addition, we observed a marked loss of CD4+ T cells in the tonsil and in the submandibular
LN draining the oral cavity, but not in the more distal axillary LN (Figure 8A). To confirm
that the decline in tonsillar CD4+ T cells was due to SIV infection rather than age, CD4+ T
cell frequencies in the infected macaques were compared to those in healthy 4-week or 11-
week old infant macaques that had not been vaccinated or challenged. The results clearly
demonstrate that in addition to the age-related decline of CD4+ T cells, SIV infection caused
further loss of CD4+ T cells in the tonsil (Figure 8A).
Consistent with the finding that infant intestinal tissues contain large numbers of T cells
with a memory/activated phenotype [24], the main targets for SIV infection, we observed a
drastic reduction of CCR5+ CD4+ T cells in the ileum and colon of the SIV-infected animals
when compared to age-matched SIV naive infant macaques (Figure 8B). Due to large
variation among animals, this difference reached statistical significance only in colonic
tissue (P<0.05 compared to infected naive and vaccinated animals, respectively).
Interestingly, the frequencies of CCR5+ CD4+ T cells in tonsils of the infected vaccine
recipients and naive controls were not reduced despite the finding above that CD4+ T cells
were depleted in the tonsil (Figure 8B). Thus, we examined the possibility that CD4+ T cell
subsets were differentially depleted in the intestine versus tonsils of the infected animals.
Despite the relatively low frequencies of CCR5+ CD4+ T cells in the tonsils, they contained
a large proportion of Ki67+ and CD25+ activated CD4+ T cells, in frequencies similar to
those in intestinal tissues (Figure 8B). Oral SIV infection reduced both intestinal Ki67+ and
CD25+ CD4+ T cells, though only the loss of CD25+ CD4+ T cells reached significance
(Figure 8B and C). In contrast, these cell populations did not decline in tonsils of SIV-
infected animals. Among the markers analyzed, a significant depletion in tonsillar CD4+ T
cells was only noted for the CD25+ FoxP3+ CD4+ T cell subset (Figure 8D). A loss of these
cells was also observed in other tissues. It is noteworthy that in the tonsil and the mesenteric
LN, the loss of CD25+ FoxP3+ CD4+ T cells was lower in the vaccinated than naive control
macaques (Figure 8D). These data suggest that in different tissues distinct CD4+T cell
populations might be preferentially depleted, and that T regulatory cells may be a major
target of SIV infection in infant macaques.
Discussion
We previously demonstrated that an oral VSV-SIV prime/systemic MVA-SIV boost vaccine
was able to induce local and systemic immune responses in mucosal and lymphoid tissues of
infant macaques [13]. The current study tested the efficacy of this vaccine regimen for
preventing oral SIV transmission in infant macaques.
Systemically administered prime-boost poxvirus-SIV vaccine strategies have shown partial
efficacy against oral SIV challenge in the infant rhesus macaque model: only a third of
ALVAC-SIV vaccinated infants became SIV-infected [12]. While infection with SIV was
not prevented in most MVA-SIV and some ALVAC-SIV vaccinated infants, the SIV-
infected vaccinated infants experienced reduced viremia and longer survival. Although the
analysis of immune parameters was limited in these earlier studies, both SIV-specific
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antibody and CD8+ T cell responses were implicated in the control of virus replication. Low
immunogenicity of ALVAC-SIV and limited protection of infant macaques after oral SIV
exposure [12] are consistent with the modest protection observed in the recent ALVAC/
AIDSVAX HIV vaccine trial in adults in the absence of persistent T cell responses [25].
To develop an improved neonatal vaccination strategy, we reasoned that oral administration
of a pediatric SIV vaccine in combination with a systemic boost would be more efficient for
preventing oral SIV transmission if it induced immune responses directly at the site of virus
entry. The VSV vector was chosen because it has proved highly immunogenic in juvenile
macaques and can be administered mucosally [26,27]. As we hypothesized, oral
administration of VSV-SIV vaccine at birth followed by i.m. boosting with MVA-SIV at 2
weeks of age did induce SIV-specific mucosal and systemic immune responses in infant
macaques [13]. However, in the current study, challenge of a new cohort of similarly
vaccinated animals at 4 weeks of age using repeated oral SIV exposure to mimic breast milk
transmission, did not prevent SIV transmission. Similar to our previous experience with
MVA- and ALVAC-SIV pediatric SIV vaccines, the VSV-SIV/MVA-SIV regimen was only
partly efficacious, based on the lower plasma viral RNA levels in vaccinated compared to
unvaccinated infant macaques.
There are three main factors that could explain the lower efficacy of the VSV-SIV/MVA-
SIV vaccine compared to our previous poxvirus only i.m. prime/boost strategies. First,
reduced efficacy could be due to use of the different VSV priming viral vector or to priming
by the oral route. Second, although the oral SIV challenge viruses used in this and previous
studies were very similar, they were not identical. Challenge stocks for both studies were
prepared from the same SIVmac251 seed stock (Table 2) and tested in adult animals to
confirm infectivity [28,29]. Finally, in the current study, two naive and two vaccinated
macaques did not become infected after the first round of oral SIV challenges. To ensure
that all controls were infected, we re-challenged these 4 infants. Thus, the current SIV
challenge regimen was more stringent than the previous single round challenge regimen.
The re-challenged animals were 3 weeks older at the time of infection, and in the 2
vaccinated animals, the vaccine-induced immune responses would have had more time to
mature. However, we consider it unlikely that the age difference at the time of challenge
significantly influenced outcome. This assumption is based on the finding that in the 2
control animals, the later challenge did not influence viremia. The 2 rechallenged animals in
the vaccine group were among the 4 that had relatively lower levels of viremia after
infection. However, only 1 rechallenged vaccinated animal (#39129) had SIV-specific
plasma IgA at the time of the second challenge and developed SIV-specific tonsillar T cells
after infection. The latter finding suggests that vaccine-induced immune responses were not
consistently improved during the 3-week period between the first and second round of
challenges.
In this study, animals were followed only for 2-3 months after challenge to assess tissue
immune responses, and therefore a long-term effect of the vaccine on survival could not be
tested. With this caveat in mind, several findings in the current study are potentially
informative to the design and application of vaccine candidates in the future. First, at the
time of challenge, SIV Env-specific IgA antibodies were detected in plasma of 6/8
vaccinated infant macaques, and these antibodies inversely correlated with peak viremia and
viral load at 4 week post-challenge. This finding is consistent with our earlier study
demonstrating that IgA antibodies, albeit at low levels, can be induced in infant macaques
by this vaccine regimen [13]. Second, the vaccinated animals that had SIV-specific T cells
in the tonsil and SIV-specific IgA in plasma and saliva after oral SIV challenge had the
lowest levels of virus replication throughout the study. We cannot infer whether SIV-
specific tonsillar T cells were present in the vaccinated infants at the time of challenge
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because tissue responses were evaluated only after challenge. In our previous study with
VSV-SIV/MVA-SIV, 2 of 5 vaccinated infants tested for tonsil responses had detectable
SIV-specific T cells at the week 4 time point [13]. Nevertheless, the postchallenge data here
implies a potentially important role of mucosal responses in the control of virus replication.
Finally, at the time of euthanasia, levels of SIV-specific IgA in plasma and salivary
inversely correlated with viremia in the group of vaccinated macaques.
One could argue that the increased detection of SIV-specific humoral and cellular responses
in VSV-SIV/MVA-SIV vaccinated animals compared to unvaccinated macaques reflected
greater preservation of CD4+ T helper cell function after SIV infection. However,
vaccinated infants that had SIV Env-specific IgA antibodies at the time of challenge, when
CD4+ T cell populations did not differ in frequencies or activation markers, also had lower
peak viremia after oral SIV challenge than unvaccinated macaques or the vaccinated infants
without detectable SIV-specific IgA. This latter finding suggests that SIV-specific IgA itself
might play a role in controlling virus replication after oral SIV challenge. However, it is
more likely that the development of SIV-specific IgA is a surrogate marker that indirectly
reflects the induction of immune responses that are needed for viral control. In this regard,
the finding that SIV infection resulted in the depletion of regulatory T cells may be highly
significant as these cells promote IgA responses [30].
Higher frequencies of central memory CD4+ T cells in the tonsils of vaccinated animals
were also associated with lower viral load in blood. This finding is consistent with studies in
adult SIV-infected macaques and HIV-1 infected humans showing that preservation of
central memory CD4+ T cells correlates with better disease prognosis [31-35]. Considering
that the tonsil is a primary site of virus replication after oral SIV challenge [11], the early
local immune response in tonsils could affect long-term disease outcome. Knowledge
concerning the cellular composition and milieu of the tonsil and how they influence virus
replication is still limited. Our data provide some evidence that the target cell populations
for SIV after oral exposure might differ between the tonsil and small intestine. Recently,
Ki67+ CD4+ T cells have been identified as major target cells for infection in infant
macaques intravenously infected with SIV [36]. Our data confirm that the tonsil and
intestine, sites of primary virus replication after oral SIV infection, contain higher
frequencies of Ki67+ CD4+ T cells than other lymphoid tissues in infant macaques. While
the decline of Ki67+ CD4+ T cells after oral SIV challenge did not reach statistical
significance, due to the large animal-to-animal variation, the higher frequencies of Ki67+
CD4+ T cells in infant compared to adult macaques (Abel, unpublished data) likely provide
a greater pool of target cells for the virus.
The frequencies of CCR5+ CD4+ T cells in the tonsil were significantly lower than the
frequencies of CCR5+ CD4+ T cells in intestinal tissues, and more similar to frequencies
observed in lymph nodes. Consistent with this observation, a significant loss of CCR5+
CD4+ T cells after oral SIV challenge was observed in intestinal tissues, but not in the tonsil.
The severe loss of CD4+ T cells in tonsils after oral SIV infection appeared to be due to
diminished frequencies of CD25+ FoxP3+ CD4+ T cells. This data is consistent with recent
studies showing a loss of Treg cells in pathogenic SIV infection [37,38], and in HIV-1
infected patients [39]. Thus, future studies should test whether SIV may preferentially infect
or result in the loss of distinct CD4+ T cell populations in different anatomic compartments.
A better understanding of the unique anatomic, cellular and immunological parameters of
the distinct tissues that serve as primary entry sites for the virus and are the portal for
dissemination is required for the development of a successful pediatric HIV vaccine to
prevent breast milk transmission.
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In summary, the oral VSV-SIV prime/ intramuscular MVA-SIV boost regimen did not
prevent oral SIV infection in infant macaques. Although the group of vaccinated animals
showed more consistent local and systemic immune responses compared to the unvaccinated
animals, a precise immunological correlate associated with reduced viremia was not
identified as tissue-specific immune responses and mucosal IgA at the time of challenge
were not assessed. After oral SIV challenge, the data indicate that virus replication is best
controlled in animals with both local and systemic antiviral IgA antibodies and with locally
induced SIV-specific T cell responses. We therefore propose that novel vaccine strategies
should aim at enhancing these local immune responses at mucosal sites of viral entry using
mucosal adjuvants and immune modulators.
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Plasma viremia and weight gain. Panels A and B show the longitudinal SIV viral levels in
the plasma of unvaccinated and vaccinated macaques, respectively. Each symbol depicts an
individual animal. The animals that were given a second round of challenges are shown in
gray. Mamu A*01 positive animals are marked with an asteriks. Data are shown in relation
to weeks post-infection (x-axis), and therefore all animals start at week 0. The black line
marks the lower limit of SIV replication (10ˆ6) at viral set point measured in unvaccinated
macaques. Panel C: Geometric means of SIV virus levels in unvaccinated (open symbol,
dashed line) compared to vaccinated macaques (closed symbol, solid line) in the first 8
weeks after SIV infection. Panel D: The average weight gain for unvaccinated (dashed line)
and vaccinated macaques (solid line) after SIV infection. The P value of <0.01 was obtained
by regression analysis.
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T cell activation and SIV-specific CD8+T cells in blood after SIV challenge. Panels A and B
show the sum of the percentages of TNF-α producing CD8+T cells after in vitro stimulation
with a SIV Gag p27 peptide pool and with AT-2 inactivated SIVmac239 in vaccinated and
unvaccinated macaques, respectively, in the first 6 weeks after SIV challenge. The average
frequencies of CCR5+ (Panel C) and Ki67+CD8+T cells (Panel D) in peripheral blood of
vaccinated (closed symbol, solid line) and unvaccinated (open symbol, dashed line)
macaques over time are presented.
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Correlations between tonsil CD4+ and CD8+ memory T cell populations and plasma viral
load at euthanasia. The percentages of central memory (TCM) (Panels A and C) and effector/
effector memory T cells (TEff ; Panels B and D) within the CD4+ (Panels A and B) or
CD8+T cell population (Panels C and D) of the tonsils of vaccinated (closed symbols) and
unvaccinated (open symbols) macaques are plotted against the SIV RNA copies per ml of
plasma in the same animals at the time of euthanasia. Note that correlations were only
statistically significant for vaccinated animals, and the P values and correlation coefficients
are presented in each of the graphs. Due to limited cell numbers, data were only available
for 5 of the 8 animals in each group (see text).
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Cytokine-producing SIV-specific CD8+T cells in the tonsil of a vaccinated animal. Top
panel: Frequencies of TNF-α producing CD8+T cells in medium and in SIVgag p27
stimulated cells. The SIV-specific TNF-α producing CD8+T cells were then further analyzed
(bottom panels) to determine their differentiation status. The first plot shows the overall
distribution of naïve (CD45RA+CCR7+), central memory (CD45RA-CCR7+) and effector/
effector memory (CD45RA+/- CCR7-) TNF-α producing CD8+T cells. The majority of TNF-
α producing cells were found in the effector/ effector memory T cell population.
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Longitudinal SIV-specific plasma IgG and IgA antibodies. Panel A: Shown are the
concentrations of IgA (Panel A) and IgA (Panel B) antibodies against SIV Env (left) and
SIV Gag, Pol (right) proteins measured by ELISA in plasma of each vaccinated and
unvaccinated macaque before and after oral SIV challenge.
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Correlation between SIV-specific antibodies and SIV replication levels. In Panel A and
Panel B the correlation between peak plasma viremia and SIV Env-specific plasma IgA and
IgG antibodies, respectively, at the time of challenge in vaccinated macaques is shown. Note
that the two animals that did not develop SIV Env-specific IgA antibodies (#37902, #38130)
were not included in Panel A, while Panel B includes all 8 vaccinees. Note that no
correlation between plasma SIV-specific IgG antibody levels at the time of challenge and
peak viremia was observed independent of whether all 8 vaccinees (see Panel B) or only the
6 vaccinated macaques (P=0.5472, r=-0.312) shown in Panel A were included in the
analysis. In Panels C and D the specific activity (ng anti-SIV IgA antibody per μg total IgA)
in plasma and saliva of each individual animal at the time of euthanasia is shown for
vaccinated (C) and unvaccinated (D) animals. Animals with lowest to highest viremia are
presented from left to right. Arrows denote salivary specimens that had specific activity than
plasma from the same animal. Panels E and F demonstrate the inverse correlation between
viral load and SIV Env (E) or SIV Gag, Pol (Panel F) IgA concentration in plasma or saliva
of vaccinated animals at the time of euthanasia.
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CD4+T cell frequencies and activation in peripheral blood. Panel A and Panel B show the
average percentages of CD3+CD4+T cells within PBMC and the absolute numbers of
CD3+CD4+T cells per microliter of blood, respectively, in peripheral blood of vaccinated
and unvaccinated macaques. In Panels C and D, the change in the frequencies of CCR5+
(Panel C) or Ki67+ (Panel D) CD4+T cells after oral SIV infection are shown. Average
values for vaccinated and unvaccinated macaques are presented with SEM.
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Activation and loss of CD4+T cells in tissues. Panel A: Shown are average percentages of
CD4+T cells within mononuclear cell populations from different tissues of age-matched (11
weeks) SIV-naïve (empty bars), unvaccinated (gray bars) and vaccinated macaques (dotted
bars) at the time of euthanasia in comparison to the normal age-related decline of CD4+T
cells in these tissues (week 4 to week 11 of age). Panel B shows the loss of activated CCR5
or Ki67-positive CD4+T cells, respectively, in tonsil and intestinal tissues of age-matched
SIV-naïve (empty bars), in unvaccinated (gray bars) and in vaccinated macaques (dotted
bars) at the time of euthanasia. In Panel C and Panel D the loss of CD25+CD4+T cells and
CD25+FoxP3+CD4+T cells in tissues of unvaccinated and vaccinated macaques compared to
SIV-naïve macaques is shown. Significant differences are indicated by the P values obtained
after comparison of the SIV-naive and unvaccinated animals, the SIV-naive and vaccinated
animals, and the unvaccinated and vaccinated animals.
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Table 2
Virus Stock
SIV Challenge Stock Parent SIV Isolate Vaccine Challenge Regimen References
SIVmac251 8/95 SIVmac251 from NENPRC* Passive (sq) SIV hyperimmune
sera
2 high doses [40]
SIVmac251 5/98 1998 SIVmac251 seed stock** 1) MVA-SIV; live attenuated
SIV
2) MVA-SIV, ALVAC-SIV
1) 2 high doses
2) 15 doses (5 days, 3x/day)
[41]
[12]
SIVmac251 2/02 1998 SIVmac251 seed stock** MVA-SIV, ALVAC-SIV
(juvenile macaques that were
vaccinated as infants)
weekly dosing until plasma
SIV positive
[12]
SIVmac251 6/04 1998 SIVmac251 seed stock** VSV-SIV and MVA-SIV one or two regimen of 15
doses (5 days, 3x/day)
current study
*
SIVmac251 was a gift from Dr. Desrosiers (NENPRC); the virus was briefly expanded on PBMC in 1995.
**
SIVmac251-8/95 was serially passaged in rhesus macaques in 1998 [42]; SIV isolated from plasma of rhesus macaque 26108 [42] was expanded
briefly on CEMx174 cells and cryopreserved to produce the 1998 seed stock which was then used to grow up future SIV challenge stocks in rhesus
PBMC [41]. To maximize viral diversity, each viral stock is the result of pooling supernatant from separate SIVmac251-infected cultures of PBMC
from 6 to 8 rhesus macaques.
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